Posts

Vol.6 No.2 – 5: Role of Human Pituitary Tumor-Transforming Gene1 (HPTTG1) as a prognostic biomarker for metastasis in Egyptian patients breast, colon and Liver cancer

/0 Comments/in , , /by

By: Samir Ali Mohamed El-Masry1, Sherif Mohsen Elsherbini1,

Abdelmoneam Ahmed Abdelmoneam2, Ahmed Gouda Ibrahim Radwan1

1-Molecular Biology department, Genetic Engineering, and Biotechnology Research Institute, Sadat City University, Egypt, 32897

2- Haemato-Oncology department, Faculty of Medicine, Banha University, Egypt, 13511

Abstract

hPTTG1 is an oncogene that overexpressed in most human carcinomas. It was reported to be involved in cell cycle regulation and sister chromatid separation.  PTTG expression level has been associated with tumor progression, invasion, and metastasis. In this study, hPTTG1 expression was analyzed in three cancer patients’ groups including; breast cancer, colorectal cancer, and hepatocellular carcinoma patients using RT-PCR. Our data revealed that the expression of PTTG1 was high in three groups; however, the metastatic cases reported higher expression levels of PTTG1 compared to non-metastatic groups. Thus, PTTG1 could be a prognostic marker in different types of cancer patients, and targeting PTTG1 might be a good strategy against metastasis.

Role of Human Pituitary Tumor-Transforming Gene1 (hPTTG1) as a prognostic biomarker in Egyptian patients breast, colon and liver cancer.

Download PDF

Vol.6 No.1 – 3: Diagnostic role of collagen III in the diagnosis of breast cancer in Egyptian women

/0 Comments/in , , /by

By: Abdelfattah M. Attallah1*, Mohamed El-Far2, Esraa A. El Sayes 1, Mohamed M. Omran3

1Research & Development Department, Biotechnology Research Center, New Damietta, Egypt

2 Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt

3 Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt

Abstract

Mammography, magnetic resonance imaging (MRI) and ultrasound are useful tools that can be used in breast cancer (BC) screening but these methods have various limitations. Thus, finding diagnostic biomarkers may be a useful alternative choice. A total of 142 females with breast diseases (40 females with benign conditions and 102 females with BC) were included in the study. In addition to age- and sex-matched 29 normal females as a negative control. The level of collagen III was detected using the ELISA technique. It was (21.29±3.14 µg/ml) in sera of females with BC higher than in benign (13.91±2.65 µg/ml) and in normal (5.69±0.43 µg/ml) females. Collagen III yielded an AUC of 0.86 to differentiate BC from normal females and an AUC of 0.62 to differentiate BC females from those with benign conditions. Moreover, AUC was risen to 0.72 to differentiate females with BC from those without BC. While the index provided values that were significantly (P<0.01) higher in BC (9.1±1.3) than benign (6.3±1.1) and normal (2.5±1.1) females. It yielded an AUC of 0.98 (sensitivity = 90.0 %) to differentiate BC from normal females and an AUC of 0.84 to differentiate BC females from those with benign conditions. Moreover,AUC was risen to 0.87 to differentiate females with BC from those without BC (sensitivity = 84.0 %).In conclusion, serum collagen III concentration represents a candidate biomarker for BC. Moreover, its combination with cancer antigen 15-3 (CA 15.3) and age provided a valuable index for BC diagnosis with high accuracy.

Diagnostic role of collagen III in diagnosis of breast cancer in Egyptian women-converted

Download PDF

Vol.4 No.4 – 10 : Breast cancer risk associated with genotype polymorphism of COMT gene in young women

/0 Comments/in , , /by

By : Abbas Ch. Mraissl

Pathology /Biology Department ,Education College , Missan University, Iraq

 

Abstract

O- methelation mediated by COMT enzyme  is an important mechanism for in activating Catechole Estrone (CE) which including 2- HE and 4- HE and transform it to 2-ME and 4-ME which act as anti- tumor genesis . Aim of this study was investigation  the association between the polymorphism in COMT genotype and the breast cancer risk in (40) young  patient’s women aged between (20-39) years were diagnosed and confirmed with breast carcinoma at AL- Sadder hospital in Missan, and (40) healthy control women aged between (18-39) years in period  between     September -2009 to April -2010 Odds ratios(OR) and confidence interval (CI) were calculated in level significant   P < 0.05. The statistical analysis showed no association between the breast cancer risk in young women and homozygous wild (Met/Met) genotype with an OR of 0.63(95%CI= 0.248 – 0.552 ), also with heterozygous  (Val/Met) genotype with an OR of 0.93 (95%CI= 0.155 – 0.44  ), and when a combination (Met/Met + Met/Val) genotype with an OR of 0.78(95%CI= 0.559-0.841), compared to homozygous mutant  (Val/Val) genotype. No significant differences in frequency of low activity alleles between cases and controls, indicating the polymorphism as a single factor may not contribute to breast carcinogenesis in young women.

Breast cancer risk associated with genotype polymorphism of COMT gene in young women-converted

Download PDF

Vol.4 No.3 – 10 : B Cell Lymphoma-2 (Bcl-2) in Serum Increased with Breast Cancer in Egyptian Women

/0 Comments/in , , /by

By : Ali Ahmad Abu Siyam1, Soheir Rizk Demian2, Ahmed Saad Ahmed3, Mohammad Abdel- Rhman Ahmad4 and Basma Hussein Mersal2.

1 Department of Medical Laboratory Sciences, Faculty of Pharmacy, Jadara University, Jordan.

2 Department of Immunology and Allergy, Medical Research Institute, University of Alexandria. Egypt.

3 Department of Clinical and Experimental Surgery, Medical Research Institute, University of Alexandria, Egypt

4 Department of Clinical Pathology and Immunology, Medical Military Academy, Alexandria Armed Forces Hospital, Egypt

Abstract

Breast cancer is the most commonly diagnosed female-spe­cific cancer, and shows an increasing trend in diagnosed cases worldwide. An estimated one in eight women will develop breast cancer in her lifetime. BC is estimated to be the most common female cancer in Egypt, and the incidence rate among Egyptian women is 48.8/105. Evasion of cell death is now acknowledged as a hallmark of cancer, required to overcome the counterbalancing effects of cell death on enhanced cell proliferation. B cell lymphoma-2 (Bcl-2) gene involves in cell survival mechanism rather than cell proliferation and it prolongs cell life by preventing apoptosis via activating different signaling routes which are induced by various agents. We aimed in this study to investigate whether the Bcl-2 activities are associated with breast cancer in Egyptian women, and correlated to different clinicopathological features of the disease. The study was conducted on forty five females; thirty women with different stages of breast cancer, and fifteen normal healthy females were included as a control group. All patients under study were subjected to full history taking and clinical examination. Fresh blood samples were obtained from all subjects, serum separation was done for measurement of Bcl-2 levels by ELISA technique. Our results showed that there were significantly higher serum Bcl-2 levels in breast cancer patients before surgery than in normal healthy controls. The results obtained also revealed that the mean value of Bcl-2 for the breast cancer patients was significantly higher than the control group. We almost can say that the Bcl-2 values would increase with advanced stages of breast cancer.

B cell lymphoma-2 (Bcl-2) in serum increased with breast cancer in Egyptian women

Download PDF